Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
Garcia-Bermudez, J. et al. Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. Nature 567, 118–122 (2019).
Cai, D. et al. RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nat. Commun. 10, 4621 (2019).
Gu, Q. et al. AIBP-mediated cholesterol efflux instructs hematopoietic stem and progenitor cell fate. Science 363, 1085–1088 (2019).
Yue, S. et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 19, 393–406 (2014).
Riscal, R., Skuli, N. & Simon, M. C. Even cancer cells watch their cholesterol. Mol. Cell 76, 220–231 (2019).
Priem, B. et al. Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell 183, 786–801.e719 (2020).
Liu, W. et al. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nat. Commun. 12, 5103 (2021).
Wang, B. et al. Phospholipid remodeling and cholesterol availability regulate intestinal stemness and tumorigenesis. Cell Stem Cell 22, 206–220.e204 (2018).
Zhang, Y. et al. Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response. Cell Cycle 18, 3337–3350 (2019).
Ikonen, E. Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell Biol. 9, 125–138 (2008).
DeBose-Boyd, R. A. & Ye, J. SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond. Trends Biochem. Sci. 43, 358–368 (2018).
Yokoyama, C. et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75, 187–197 (1993).
Hua, X. et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl Acad. Sci. USA 90, 11603–11607 (1993).
Lee, S. H., Lee, J. H. & Im, S. S. The cellular function of SCAP in metabolic signaling. Exp. Mol. Med. 52, 724–729 (2020).
Luo, J., Yang, H. & Song, B. L. Mechanisms and regulation of cholesterol homeostasis. Nat. Rev. Mol. Cell Biol. 21, 225–245 (2020).
Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340 (1997).
Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131 (2002).
Meng, Y., Heybrock, S., Neculai, D. & Saftig, P. Cholesterol handling in lysosomes and beyond. Trends Cell Biol. 30, 452–466 (2020).
Meyer, J. M., Graf, G. A. & van der Westhuyzen, D. R. New developments in selective cholesteryl ester uptake. Curr. Opin. Lipido. 24, 386–392 (2013).
Papale, G. A., Hanson, P. J. & Sahoo, D. Extracellular disulfide bonds support scavenger receptor class B type I-mediated cholesterol transport. Biochemistry 50, 6245–6254 (2011).
Guo, L., Chen, M., Song, Z., Daugherty, A. & Li, X. A. C323 of SR-BI is required for SR-BI-mediated HDL binding and cholesteryl ester uptake. J. Lipid Res. 52, 2272–2278 (2011).
Rigotti, A. et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc. Natl Acad. Sci. USA 94, 12610–12615 (1997).
Viñals, M., Xu, S., Vasile, E. & Krieger, M. Identification of the N-linked glycosylation sites on the high density lipoprotein (HDL) receptor SR-BI and assessment of their effects on HDL binding and selective lipid uptake. J. Biol. Chem. 278, 5325–5332 (2003).
Sharma, B. & Agnihotri, N. Role of cholesterol homeostasis and its efflux pathways in cancer progression. J. Steroid Biochem. Mol. Biol. 191, 105377 (2019).
Chang, T. Y., Chang, C. C. & Cheng, D. Acyl-coenzyme A:cholesterol acyltransferase. Annu. Rev. Biochem 66, 613–638 (1997).
Chang, T. Y., Chang, C. C., Ohgami, N. & Yamauchi, Y. Cholesterol sensing, trafficking, and esterification. Annu. Rev. Cell Dev. Biol. 22, 129–157 (2006).
Xu, D. et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature 580, 530–535 (2020).
Vallejo, F. A. et al. The contribution of ketone bodies to glycolytic inhibition for the treatment of adult and pediatric glioblastoma. J. Neurooncol. 147, 317–326 (2020).
van Reyk, D. M., Brown, A. J., Hult’en, L. M., Dean, R. T. & Jessup, W. Oxysterols in biological systems: sources, metabolism and pathophysiological relevance. Redox Rep. 11, 255–262 (2006).
Vejux, A. & Lizard, G. Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. Mol. Asp. Med. 30, 153–170 (2009).
Norlin, M. & Wikvall, K. Enzymes in the conversion of cholesterol into bile acids. Curr. Mol. Med. 7, 199–218 (2007).
Yoshida, Y., Umeno, A. & Shichiri, M. Lipid peroxidation biomarkers for evaluating oxidative stress and assessing antioxidant capacity in vivo. J. Clin. Biochem. Nutr. 52, 9–16 (2013).
Brown, M. S., Radhakrishnan, A. & Goldstein, J. L. Retrospective on cholesterol homeostasis: the central role of scap. Annu Rev. Biochem. 87, 783–807 (2018).
Kaneko, R. et al. Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J. Biol. Chem. 282, 19273–19281 (2007).
Radhakrishnan, A., Ikeda, Y., Kwon, H. J., Brown, M. S. & Goldstein, J. L. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl Acad. Sci. USA 104, 6511–6518 (2007).
Horton, J. D. et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl Acad. Sci. USA 100, 12027–12032 (2003).
Luu, W., Sharpe, L. J., Stevenson, J. & Brown, A. J. Akt acutely activates the cholesterogenic transcription factor SREBP-2. Biochim. Biophys. Acta 1823, 458–464 (2012).
Eid, W. et al. mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells. Proc. Natl Acad. Sci. USA 114, 7999–8004 (2017).
Jiang, Z. et al. Hepatic deficiency of Poldip2 in type 2 diabetes dampens lipid and glucose homeostasis. Metabolism 99, 90–101 (2019).
Moon, S. H. et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell 176, 564–580.e519 (2019).
Parrales, A. et al. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat. Cell Biol. 18, 1233–1243 (2016).
Kaymak, I. et al. Mevalonate pathway provides ubiquinone to maintain pyrimidine synthesis and survival in p53-deficient cancer cells exposed to metabolic stress. Cancer Res. 80, 189–203 (2020).
Hashimoto, M. et al. Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate. J. Steroid Biochem. Mol. Biol. 163, 121–128 (2016).
Deng, Y. Z. et al. Cilia loss sensitizes cells to transformation by activating the mevalonate pathway. J. Exp. Med. 215, 177–195 (2018).
Zhao, S. et al. MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway. Cell Death Dis. 12, 18 (2021).
Wang, B. & Tontonoz, P. Liver X receptors in lipid signalling and membrane homeostasis. Nat. Rev. Endocrinol. 14, 452–463 (2018).
Bakiri, L. et al. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. J. Exp. Med 214, 1387–1409 (2017).
Ma, L. & Nelson, E. R. Oxysterols and nuclear receptors. Mol. Cell Endocrinol. 484, 42–51 (2019).
Janowski, B. A. et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl Acad. Sci. USA 96, 266–271 (1999).
Mutemberezi, V., Guillemot-Legris, O. & Muccioli, G. G. Oxysterols: from cholesterol metabolites to key mediators. Prog. Lipid Res 64, 152–169 (2016).
Santori, F. R. et al. Identification of natural RORγ ligands that regulate the development of lymphoid cells. Cell Metab. 21, 286–298 (2015).
Voisin, M. et al. Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. Proc. Natl Acad. Sci. USA 114, E9346–e9355 (2017).
Huang, B., Song, B. L. & Xu, C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat. Metab. 2, 132–141 (2020).
Nelson, E. R. et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342, 1094–1098 (2013).
Gibson, D. A., Collins, F., Cousins, F. L., Esnal Zufiaurre, A. & Saunders, P. T. K. The impact of 27-hydroxycholesterol on endometrial cancer proliferation. Endocr. Relat. Cancer 25, 381–391 (2018).
Wang, S., Yao, Y., Rao, C., Zheng, G. & Chen, W. 25-HC decreases the sensitivity of human gastric cancer cells to 5-fluorouracil and promotes cells invasion via the TLR2/NF-κB signaling pathway. Int. J. Oncol. 54, 966–980 (2019).
Eibinger, G. et al. On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment. Exp. Cell Res. 319, 1828–1838 (2013).
Jo, Y., Lee, P. C., Sguigna, P. V. & DeBose-Boyd, R. A. Sterol-induced degradation of HMG CoA reductase depends on interplay of two Insigs and two ubiquitin ligases, gp78 and Trc8. Proc. Natl Acad. Sci. USA 108, 20503–20508 (2011).
Menzies, S. A. et al. The sterol-responsive RNF145 E3 ubiquitin ligase mediates the degradation of HMG-CoA reductase together with gp78 and Hrd1. Elife 7, https://doi.org/10.7554/eLife.40009 (2018).
Tsai, Y. C. et al. Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol. Biol. Cell 23, 4484–4494 (2012).
Zelcer, N. et al. The E3 ubiquitin ligase MARCH6 degrades squalene monooxygenase and affects 3-hydroxy-3-methyl-glutaryl coenzyme A reductase and the cholesterol synthesis pathway. Mol. Cell Biol. 34, 1262–1270 (2014).
Chen, L. et al. Endogenous sterol intermediates of the mevalonate pathway regulate HMGCR degradation and SREBP-2 processing. J. Lipid Res. 60, 1765–1775 (2019).
Song, B. L., Javitt, N. B. & DeBose-Boyd, R. A. Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell Metab. 1, 179–189 (2005).
Song, B. L. & DeBose-Boyd, R. A. Ubiquitination of 3-hydroxy-3-methylglutaryl-CoA reductase in permeabilized cells mediated by cytosolic E1 and a putative membrane-bound ubiquitin ligase. J. Biol. Chem. 279, 28798–28806 (2004).
Sharpe, L. J., Coates, H. W. & Brown, A. J. Post-translational control of the long and winding road to cholesterol. J. Biol. Chem. 295, 17549–17559 (2020).
Soto-Acosta, R., Bautista-Carbajal, P., Cervantes-Salazar, M., Angel-Ambrocio, A. H. & Del Angel, R. M. DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: a potential antiviral target. PLoS Pathog. 13, e1006257 (2017).
Kondo, A. et al. Extracellular acidic pH activates the sterol regulatory element-binding protein 2 to promote tumor progression. Cell Rep. 18, 2228–2242 (2017).
Wang, M. & Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14, 581–597 (2014).
Dang, E. V., McDonald, J. G., Russell, D. W. & Cyster, J. G. Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation. Cell 171, 1057–1071.e1011 (2017).
Zhang, K. L. et al. Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics 11, 6560–6572 (2021).
Wagschal, A. et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat. Med. 21, 1290–1297 (2015).
Cheng, L. et al. MicroRNA-148a deficiency promotes hepatic lipid metabolism and hepatocarcinogenesis in mice. Cell Death Dis. 8, e2916 (2017).
Singaravelu, R. et al. MicroRNAs regulate the immunometabolic response to viral infection in the liver. Nat. Chem. Biol. 11, 988–993 (2015).
Wang, L. et al. MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol. Cell Biol. 33, 1956–1964 (2013).
Wang, M. et al. Obesity-induced overexpression of miRNA-24 regulates cholesterol uptake and lipid metabolism by targeting SR-B1. Gene 668, 196–203 (2018).
Fernández-Hernando, C. & Moore, K. J. MicroRNA modulation of cholesterol homeostasis. Arterioscler Thromb. Vasc. Biol. 31, 2378–2382 (2011).
Zhao, L. et al. miR-33-5p knockdown attenuates abdominal aortic aneurysm progression via promoting target adenosine triphosphate-binding cassette transporter A1 expression and activating the PI3K/Akt signaling pathway. Perfusion 35, 57–65 (2020).
Tang, X. E. et al. IL-8 negatively regulates ABCA1 expression and cholesterol efflux via upregulating miR-183 in THP-1 macrophage-derived foam cells. Cytokine 122, 154385 (2019).
Bi, D. P., Yin, C. H., Zhang, X. Y., Yang, N. N. & Xu, J. Y. MiR-183 functions as an oncogene by targeting ABCA1 in colon cancer. Oncol. Rep. 35, 2873–2879 (2016).
Liang, B. et al. MicroRNA-20a/b regulates cholesterol efflux through post-transcriptional repression of ATP-binding cassette transporter A1. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1862, 929–938 (2017).
Lv, Y. C. et al. MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1. Atherosclerosis 236, 215–226 (2014).
Ramirez, C. M. et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb. Vasc. Biol. 31, 2707–2714 (2011).
Sun, D. et al. MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. FEBS Lett. 586, 1472–1479 (2012).
Wu, Q. et al. Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget 5, 11552–11563 (2014).
Huang, J., Chen, S., Cai, D., Bian, D. & Wang, F. Long noncoding RNA lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathway. Life Sci. 203, 48–53 (2018).
Cui, M. et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res. 75, 846–857 (2015).
Gast, M. et al. Long noncoding RNA NEAT1 modulates immune cell functions and is suppressed in early onset myocardial infarction patients. Cardiovasc. Res. 115, 1886–1906 (2019).
Reichert, S., Seitter, L., Schaller, H. G., Schlitt, A. & Schulz, S. ANRIL polymorphisms (rs1333049 and rs3217992) in relation to plasma CRP levels among in-patients with CHD. Cytokine 127, 154932 (2020).
Liu, L., Tan, L., Yao, J. & Yang, L. Long non‑coding RNA MALAT1 regulates cholesterol accumulation in ox‑LDL‑induced macrophages via the microRNA‑17‑5p/ABCA1 axis. Mol. Med. Rep. 21, 1761–1770 (2020).
Liu, X. et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature 588, 693–698 (2020).
Kopecka, J., Godel, M. & Riganti, C. Cholesterol metabolism: at the cross road between cancer cells and immune environment. Int. J. Biochem. Cell Biol. 129, 105876 (2020).
Villablanca, E. J. et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16, 98–105 (2010).
Baek, A. E. et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat. Commun. 8, 864 (2017).
Goossens, P. et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 29, 1376–1389.e1374 (2019).
Bhattacharya, A., Chowdhury, A., Chaudhury, K. & Shukla, P. C. Proprotein convertase subtilisin/kexin type 9 (PCSK9): a potential multifaceted player in cancer. Biochim. Biophys. Acta Rev. Cancer 1876, 188581 (2021).
Stoekenbroek, R. M., Lambert, G., Cariou, B. & Hovingh, G. K. Inhibiting PCSK9 – biology beyond LDL control. Nat. Rev. Endocrinol. 15, 52–62 (2018).
Yuan, J. et al. Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. Protein Cell 12, 240–260 (2021).
Yang, W. et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 531, 651–655 (2016).
Ma, X. et al. Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment. Cell Metab. 30, 143–156.e145 (2019).
Kaser, A. et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134, 743–756 (2008).
Yang, Z. et al. Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production. Cell Metab. https://doi.org/10.1016/j.cmet.2022.10.010 (2022).
Lu, Z. et al. ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes. Cell Metab. 34, 1342–1358.e1347 (2022).
Qin, W. H. et al. High serum levels of cholesterol increase antitumor functions of nature killer cells and reduce growth of liver tumors in mice. Gastroenterology 158, 1713–1727 (2020).
O’Brien, K. L. et al. De novo polyamine synthesis supports metabolic and functional responses in activated murine NK cells. Eur. J. Immunol. 51, 91–102 (2021).
Forcina, G. C. & Dixon, S. J. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics 19, e1800311 (2019).
Warner, G. J. et al. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J. Biol. Chem. 275, 28110–28119 (2000).
Bersuker, K. et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688–692 (2019).
Shimada, K. et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 12, 497–503 (2016).
Hurst, R. et al. Hyperresistance to cholesterol hydroperoxide-induced peroxidative injury and apoptotic death in a tumor cell line that overexpresses glutathione peroxidase isotype-4. Free Radic. Biol. Med. 31, 1051–1065 (2001).
Ng, M. Y. W. et al. The cholesterol transport protein GRAMD1C regulates autophagy initiation and mitochondrial bioenergetics. Nat. Commun. 13, 6283 (2022).
Snaebjornsson, M. T., Janaki-Raman, S. & Schulze, A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. 31, 62–76 (2020).
Pan, Q. et al. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. Mol. Cell 81, 2736–2751.e2738 (2021).
Li, N. et al. ZMYND8 reads the dual histone mark H3K4me1-H3K14ac to antagonize the expression of metastasis-linked genes. Mol. Cell 63, 470–484 (2016).
Yang, L. et al. Oxidized low-density lipoprotein links hypercholesterolemia and bladder cancer aggressiveness by promoting cancer stemness. Cancer Res. 81, 5720–5732 (2021).
Kim, H. Y. et al. Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness. Exp. Mol. Med. 50, 1–12 (2018).
Krüger, K. et al. Lovastatin prevents cisplatin-induced activation of pro-apoptotic DNA damage response (DDR) of renal tubular epithelial cells. Toxicol. Appl. Pharm. 292, 103–114 (2016).
Pääjärvi, G., Roudier, E., Crisby, M., Högberg, J. & Stenius, U. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J. 19, 476–478 (2005).
Xu, H., Zhou, S., Tang, Q., Xia, H. & Bi, F. Cholesterol metabolism: new functions and therapeutic approaches in cancer. Biochim. Biophys. Acta Rev. Cancer 1874, 188394 (2020).
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E. & Penn, L. Z. Statins as anticancer agents in the era of precision medicine. Clin. Cancer Res. 26, 5791–5800 (2020).
Rao, S. et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl Acad. Sci. USA 96, 7797–7802 (1999).
Kotamraju, S., Williams, C. L. & Kalyanaraman, B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 67, 7386–7394 (2007).
Qi, X. F. et al. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis. 4, e518 (2013).
Sahebkar, A., Ponziani, M. C., Goitre, I. & Bo, S. Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials. Metabolism 64, 1466–1476 (2015).
Woodard, J., Sassano, A., Hay, N. & Platanias, L. C. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin. Cancer Res. 14, 4640–4649 (2008).
Swanson, K. M. & Hohl, R. J. Anti-cancer therapy: targeting the mevalonate pathway. Curr. Cancer Drug Targets 6, 15–37 (2006).
Prabhu, N. et al. Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy. Urol. Oncol. 39, 130.e139–130.e115 (2021).
Duncan, R. E., El-Sohemy, A. & Archer, M. C. Statins and the risk of cancer. Jama 295, 2720 (2006). author reply 2721-2722.
Ahern, T. P. et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J. Natl Cancer Inst. 103, 1461–1468 (2011).
Manthravadi, S., Shrestha, A. & Madhusudhana, S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int. J. Cancer 139, 1281–1288 (2016).
Xia, Y. et al. The mevalonate pathway is a druggable target for vaccine adjuvant discovery. Cell 175, 1059–1073.e1021 (2018).
Abdel-Rahman, O. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Clin. Transl. Oncol. 21, 810–816 (2019).
Brånvall, E. et al. Statin use is associated with improved survival in multiple myeloma: a Swedish population-based study of 4315 patients. Am. J. Hematol. 95, 652–661 (2020).
Cardwell, C. R., Hicks, B. M., Hughes, C. & Murray, L. J. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J. Clin. Oncol. 32, 3177–3183 (2014).
Lee, Y. et al. Randomized phase II study of afatinib plus simvastatin versus afatinib alone in previously treated patients with advanced nonadenocarcinomatous non-small cell lung cancer. Cancer Res Treat. 49, 1001–1011 (2017).
Garwood, E. R. et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 119, 137–144 (2010).
Pandyra, A. et al. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. Cancer Res. 74, 4772–4782 (2014).
Gaist, D., Hallas, J., Friis, S., Hansen, S. & Sørensen, H. T. Statin use and survival following glioblastoma multiforme. Cancer Epidemiol. 38, 722–727 (2014).
Han, J. Y. et al. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 17, 1553–1560 (2011).
Göbel, A., Rauner, M., Hofbauer, L. C. & Rachner, T. D. Cholesterol and beyond—the role of the mevalonate pathway in cancer biology. Biochim. Biophys. Acta Rev. Cancer 1873, 188351 (2020).
Van Acker, H. H., Anguille, S., Willemen, Y., Smits, E. L. & Van Tendeloo, V. F. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. Pharm. Ther. 158, 24–40 (2016).
Gralow, J. R. et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J. Natl Cancer Inst. 112, 698–707 (2020).
Maione, F. et al. The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Sci. Rep. 5, 9054 (2015).
Li, C. et al. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. Gut 71, 2253–2265 (2022).
Trinh, M. N. et al. Triazoles inhibit cholesterol export from lysosomes by binding to NPC1. Proc. Natl Acad. Sci. USA 114, 89–94 (2017).
Lu, F. et al. Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection. Elife 4, https://doi.org/10.7554/eLife.12177 (2015).
Rossebø, A. B. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359, 1343–1356 (2008).
Lincoff, A. M. et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N. Engl. J. Med. 376, 1933–1942 (2017).
Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).
Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
Kamanna, V. S. & Kashyap, M. L. Mechanism of action of niacin. Am. J. Cardiol. 101, 20b–26b (2008).
Yang, S. et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Natl Acad. Sci. USA 110, 2511–2516 (2013).
Flaveny, C. A. et al. Broad anti-tumor activity of a small molecule that selectively targets the warburg effect and lipogenesis. Cancer Cell 28, 42–56 (2015).
Wu, G. et al. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist. Cell Death Dis. 10, 416 (2019).
He, P., Smith, A., Gelissen, I. C. & Ammit, A. J. The effect of statins and the synthetic LXR agonist T0901317 on expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro. Pharm. Rep. 71, 1219–1226 (2019).
Liang, H. & Shen, X. LXR activation radiosensitizes non-small cell lung cancer by restricting myeloid-derived suppressor cells. Biochem. Biophys. Res. Commun. 528, 330–335 (2020).
Lei, J., Wang, H., Zhu, D., Wan, Y. & Yin, L. Combined effects of avasimibe immunotherapy, doxorubicin chemotherapy, and metal-organic frameworks nanoparticles on breast cancer. J. Cell Physiol. 235, 4814–4823 (2020).
Li, J. et al. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene 35, 6378–6388 (2016).
Pan, J. et al. Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator. EBioMedicine 49, 72–81 (2019).
Zhao, L. et al. Cholesterol esterification enzyme inhibition enhances antitumor effects of human chimeric antigen receptors modified T cells. J. Immunother. 41, 45–52 (2018).
Bandyopadhyay, S. et al. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS ONE 12, e0179558 (2017).